- Trials with a EudraCT protocol (1,053)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
1,053 result(s) found for: Liver tumors.
Displaying page 1 of 53.
EudraCT Number: 2004-002205-69 | Sponsor Protocol Number: Hepatooma | Start Date*: 2009-08-24 |
Sponsor Name:Organisation name was not entered | ||
Full Title: Investigation of Hepatic Tumors with Positron Emission Tomography Using [11C]-Metomidate and [11C]-Acetate Tracers | ||
Medical condition: This study is planned to determine and compare two new radiotracers (11C-labeled metomidate and acetate) in the detection of malignant and benign hepatic tumors. The detection of hepatocellular car... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003028-22 | Sponsor Protocol Number: RGT100-001 | Start Date*: 2017-01-26 | |||||||||||||||||||||
Sponsor Name:Rigontec GmbH | |||||||||||||||||||||||
Full Title: A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors | |||||||||||||||||||||||
Medical condition: Advanced or recurrent tumors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000232-34 | Sponsor Protocol Number: NASIR-HCC | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment o... | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006097-76 | Sponsor Protocol Number: LOTUS | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO... | |||||||||||||
Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000369-54 | Sponsor Protocol Number: 60725 | Start Date*: 2018-06-27 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases | ||
Medical condition: Patients with neuro-endocrine tumors with liver metastases with an indication for treatment with lutetium-177-dotatate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002985-70 | Sponsor Protocol Number: MD-R20080507 | Start Date*: 2009-04-23 |
Sponsor Name:University of Magdeburg | ||
Full Title: Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial. | ||
Medical condition: Irradiation damage to the liver after HDR-brachytherapy of liver metastases. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005386-67 | Sponsor Protocol Number: 20140318 | Start Date*: 2017-03-27 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an... | ||||||||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000252-34 | Sponsor Protocol Number: CA2099DW | Start Date*: 2020-02-17 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma | ||||||||||||||||||
Medical condition: Hepatocellular Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005609-21 | Sponsor Protocol Number: RAD50 | Start Date*: 2009-08-03 | |||||||||||
Sponsor Name:Faculty For Medicine, Otto-von-Guericke University Magdeburg | |||||||||||||
Full Title: Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors. | |||||||||||||
Medical condition: In addition to the assessment of shunt volumes, the intrahepatic distribution of MAA may allow for prediction of tumor radiation dose and the radiation dose to normal liver tissue. Even though MAA ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003151-38 | Sponsor Protocol Number: CA224-073 | Start Date*: 2020-12-14 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kin... | ||||||||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002755-29 | Sponsor Protocol Number: CA209-9DX | Start Date*: 2018-11-19 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or ... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023032-17 | Sponsor Protocol Number: CRAD001K24133 | Start Date*: 2011-04-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors | ||
Medical condition: The study will evaluate the safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal, lung or pancreatic origin. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) SE (Prematurely Ended) GR (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013707-63 | Sponsor Protocol Number: 1 | Start Date*: 2010-03-05 |
Sponsor Name:C.U.B ERASME HOSPITAL | ||
Full Title: POSTOPERATIVE ANALGESIA USING PREPERITONEAL CONTINUOUS INFUSIONS OF ROPIVACAINE IN PATIENTS UNDERGOING LIVER SURGERY -CONSEQUENCES ON ROPIVACAINE METABOLISM | ||
Medical condition: PATIENTS WITH HEPATIC TUMORS BUT WITH A GOOD HEPATIC FUNCTION BEFORE SURGERY | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000863-56 | Sponsor Protocol Number: HP-HCC | Start Date*: 2021-05-04 | |||||||||||
Sponsor Name:Aarhus University, The MR Research Center | |||||||||||||
Full Title: Early detection of hepatocellular carcinoma by Hyperpolarized [1-13C]pyruvate MRI | |||||||||||||
Medical condition: Primary liver cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001770-40 | Sponsor Protocol Number: 11546 | Start Date*: 2005-06-03 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma. | |||||||||||||
Medical condition: advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003023-38 | Sponsor Protocol Number: CHUBX2017/47 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in pa... | |||||||||||||
Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005546-63 | Sponsor Protocol Number: DOTATER1_26_15 | Start Date*: 2016-05-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA | |||||||||||||
Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors. | |||||||||||||
Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003213-34 | Sponsor Protocol Number: CH2012-001 | Start Date*: 2012-11-13 | |||||||||||
Sponsor Name:ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: MEthylprednisoloneNacinHepatIcResections “MENHIR” | |||||||||||||
Medical condition: patients candidate to liver resection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001773-26 | Sponsor Protocol Number: 100554 | Start Date*: 2005-05-03 | |||||||||||
Sponsor Name:Bayer HealthCare AG, D-51368 Leverkusen Germany | |||||||||||||
Full Title: A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma | |||||||||||||
Medical condition: Advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003768-30 | Sponsor Protocol Number: IEO906 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors | |||||||||||||
Medical condition: Pancreatic neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
